Michael Chong1,2, Jennifer Sjaarda1, Marie Pigeyre1, Pedrum Mohammadi-Shemirani1,3, Ricky Lali1, Ashkan Shoamanesh1,4, Hertzel Chaim Gerstein1,5, Guillaume Paré1,2,5,6. 1. Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, Ontario, Canada (M.C., J.S., M.P., P.M.-S., R.L., A.S., H.C.G., G.P.). 2. Departments of Biochemistry (M.C., G.P.). 3. Medical Sciences (P.M.-S.). 4. Medicine, Division of Neurology, McMaster University, Hamilton, Ontario, Canada (A.S.). 5. Clinical Epidemiology and Biostatistics (H.C.G., G.P.). 6. Pathology and Molecular Medicine (G.P.).
Abstract
BACKGROUND: Novel, effective, and safe drugs are warranted for treatment of ischemic stroke. Circulating protein biomarkers with causal genetic evidence represent promising drug targets, but no systematic screen of the proteome has been performed. METHODS: First, using Mendelian randomization (MR) analyses, we assessed 653 circulating proteins as possible causal mediators for 3 different subtypes of ischemic stroke: large artery atherosclerosis, cardioembolic stroke, and small artery occlusion. Second, we used MR to assess whether identified biomarkers also affect risk for intracranial bleeding, specifically intracerebral and subarachnoid hemorrhages. Third, we expanded this analysis to 679 diseases to test a broad spectrum of side effects associated with hypothetical therapeutic agents for ischemic stroke that target the identified biomarkers. For all MR analyses, summary-level data from genome-wide association studies (GWAS) were used to ascertain genetic effects on circulating biomarker levels versus disease risk. Biomarker effects were derived by meta-analysis of 5 GWAS (N≤20 509). Disease effects were derived from large GWAS analyses, including MEGASTROKE (N≤322 150) and UK Biobank (N≤408 961) studies. RESULTS: Several biomarkers emerged as causal mediators for ischemic stroke. Causal mediators for cardioembolic stroke included histo-blood group ABO system transferase, coagulation factor XI, scavenger receptor class A5 (SCARA5), and tumor necrosis factor-like weak inducer of apoptosis (TNFSF12). Causal mediators for large artery atherosclerosis included ABO, cluster of differentiation 40, apolipoprotein(a), and matrix metalloproteinase-12. SCARA5 (odds ratio [OR]=0.78; 95% CI, 0.70-0.88; P=1.46×10-5) and TNFSF12 (OR=0.86; 95% CI, 0.81-0.91; P=7.69×10-7) represent novel protective mediators of cardioembolic stroke. TNFSF12 also increased the risk of subarachnoid (OR=1.53; 95% CI, 1.31-1.78; P=3.32×10-8) and intracerebral (OR=1.34; 95% CI, 1.14-1.58; P=4.05×10-4) hemorrhages, whereas SCARA5 decreased the risk of subarachnoid hemorrhage (OR=0.61; 95% CI, 0.47-0.81; P=5.20×10-4). Multiple side effects beyond stroke were identified for 6 of 7 biomarkers, most (75%) of which were beneficial. No adverse side effects were found for coagulation factor XI, apolipoprotein(a), and SCARA5. CONCLUSIONS: Through a systematic MR screen of the circulating proteome, causal roles for 5 established and 2 novel biomarkers for ischemic stroke were identified. Side-effect profiles were characterized to help inform drug target prioritization. In particular, SCARA5 represents a promising target for treatment of cardioembolic stroke, with no predicted adverse side effects.
BACKGROUND: Novel, effective, and safe drugs are warranted for treatment of ischemic stroke. Circulating protein biomarkers with causal genetic evidence represent promising drug targets, but no systematic screen of the proteome has been performed. METHODS: First, using Mendelian randomization (MR) analyses, we assessed 653 circulating proteins as possible causal mediators for 3 different subtypes of ischemic stroke: large artery atherosclerosis, cardioembolic stroke, and small artery occlusion. Second, we used MR to assess whether identified biomarkers also affect risk for intracranial bleeding, specifically intracerebral and subarachnoid hemorrhages. Third, we expanded this analysis to 679 diseases to test a broad spectrum of side effects associated with hypothetical therapeutic agents for ischemic stroke that target the identified biomarkers. For all MR analyses, summary-level data from genome-wide association studies (GWAS) were used to ascertain genetic effects on circulating biomarker levels versus disease risk. Biomarker effects were derived by meta-analysis of 5 GWAS (N≤20 509). Disease effects were derived from large GWAS analyses, including MEGASTROKE (N≤322 150) and UK Biobank (N≤408 961) studies. RESULTS: Several biomarkers emerged as causal mediators for ischemic stroke. Causal mediators for cardioembolic stroke included histo-blood group ABO system transferase, coagulation factor XI, scavenger receptor class A5 (SCARA5), and tumor necrosis factor-like weak inducer of apoptosis (TNFSF12). Causal mediators for large artery atherosclerosis included ABO, cluster of differentiation 40, apolipoprotein(a), and matrix metalloproteinase-12. SCARA5 (odds ratio [OR]=0.78; 95% CI, 0.70-0.88; P=1.46×10-5) and TNFSF12 (OR=0.86; 95% CI, 0.81-0.91; P=7.69×10-7) represent novel protective mediators of cardioembolic stroke. TNFSF12 also increased the risk of subarachnoid (OR=1.53; 95% CI, 1.31-1.78; P=3.32×10-8) and intracerebral (OR=1.34; 95% CI, 1.14-1.58; P=4.05×10-4) hemorrhages, whereas SCARA5 decreased the risk of subarachnoid hemorrhage (OR=0.61; 95% CI, 0.47-0.81; P=5.20×10-4). Multiple side effects beyond stroke were identified for 6 of 7 biomarkers, most (75%) of which were beneficial. No adverse side effects were found for coagulation factor XI, apolipoprotein(a), and SCARA5. CONCLUSIONS: Through a systematic MR screen of the circulating proteome, causal roles for 5 established and 2 novel biomarkers for ischemic stroke were identified. Side-effect profiles were characterized to help inform drug target prioritization. In particular, SCARA5 represents a promising target for treatment of cardioembolic stroke, with no predicted adverse side effects.
Authors: Dipender Gill; Marios K Georgakis; Venexia M Walker; A Floriaan Schmidt; Apostolos Gkatzionis; Daniel F Freitag; Chris Finan; Aroon D Hingorani; Joanna M M Howson; Stephen Burgess; Daniel I Swerdlow; George Davey Smith; Michael V Holmes; Martin Dichgans; Robert A Scott; Jie Zheng; Bruce M Psaty; Neil M Davies Journal: Wellcome Open Res Date: 2021-02-10
Authors: Benton Maglinger; Jacqueline A Frank; Christopher J McLouth; Amanda L Trout; Jill Marie Roberts; Stephen Grupke; Jadwiga Turchan-Cholewo; Ann M Stowe; Justin F Fraser; Keith R Pennypacker Journal: J Neurointerv Surg Date: 2020-07-08 Impact factor: 5.836
Authors: Yvonne Alexander; Elena Osto; Arno Schmidt-Trucksäss; Michael Shechter; Danijela Trifunovic; Dirk J Duncker; Victor Aboyans; Magnus Bäck; Lina Badimon; Francesco Cosentino; Marco De Carlo; Maria Dorobantu; David G Harrison; Tomasz J Guzik; Imo Hoefer; Paul D Morris; Giuseppe D Norata; Rosa Suades; Stefano Taddei; Gemma Vilahur; Johannes Waltenberger; Christian Weber; Fiona Wilkinson; Marie-Luce Bochaton-Piallat; Paul C Evans Journal: Cardiovasc Res Date: 2021-01-01 Impact factor: 10.787
Authors: Andrew D Bretherick; Oriol Canela-Xandri; Peter K Joshi; David W Clark; Konrad Rawlik; Thibaud S Boutin; Yanni Zeng; Carmen Amador; Pau Navarro; Igor Rudan; Alan F Wright; Harry Campbell; Veronique Vitart; Caroline Hayward; James F Wilson; Albert Tenesa; Chris P Ponting; J Kenneth Baillie; Chris Haley Journal: PLoS Genet Date: 2020-07-06 Impact factor: 5.917
Authors: William N Whiteley; Sonia Anand; Shrikant I Bangdiwala; Jackie Bosch; Michelle Canavan; Howard Chertkow; Hertzel C Gerstein; Philip Gorelick; Martin O'Donnell; Guillaume Paré; Marie Pigeyre; Sudha Seshadri; Mike Sharma; Eric E Smith; Jeff Williamson; Tali Cukierman-Yaffe; Robert G Hart; Salim Yusuf Journal: Age Ageing Date: 2020-02-27 Impact factor: 10.668
Authors: Jie Zheng; Valeriia Haberland; Denis Baird; Venexia Walker; Philip C Haycock; Mark R Hurle; Alex Gutteridge; Pau Erola; Yi Liu; Shan Luo; Jamie Robinson; Tom G Richardson; James R Staley; Benjamin Elsworth; Stephen Burgess; Benjamin B Sun; John Danesh; Heiko Runz; Joseph C Maranville; Hannah M Martin; James Yarmolinsky; Charles Laurin; Michael V Holmes; Jimmy Z Liu; Karol Estrada; Rita Santos; Linda McCarthy; Dawn Waterworth; Matthew R Nelson; George Davey Smith; Adam S Butterworth; Gibran Hemani; Robert A Scott; Tom R Gaunt Journal: Nat Genet Date: 2020-09-07 Impact factor: 38.330